Recombinant therapeutic antibodies consolidate as growth driver of biologics sales in 2013
- Category: Press Room
- Published on Friday, 09 May 2014 16:38
- Hits: 7139
STUTTGART, Germany I May 9, 2014 I La Merie Publishing announced today the release of its annual review of the sales of recombinant therapeutic antibodies and proteins. The compilation entitled „2013 Sales of Recombinant Therapeutic Antibodies & Proteins“ shows that total sales of recombinant biologics increased by 12% from US$ 125 bln in the year 2012 to US$ 140 bln in the year 2013. The relative contribution of recombinant antibodies to the total sales of therapeutic biologics further grew from 51.7% in 2012 to 54.1% in 2013, not only driven by stronger growth of the class of antibodies, but also by decrease of sales of several therapeutic protein classes, e.g. erythropoietin and interferon alpha.
The number of blockbuster biologics, i.e. with annual sales of more than US$ 1 bln, again increased to 38 in the year 2013 (vs. 33 in 2012). Among the TOP 10 best selling blockbuster biologic products are seven therapeutic antibodies. The only blockbuster biologic with 2013 sales of more than US$ 10 bln was the anti-TNF antibody adalimumab (Humira, from AbbVie), driven by a strong 15% growth of sales vs the previous year. TNF antibodies represent the biologic product class with highest sales in 2013, but the class of other anti-inflammatory antibodies showed the highest growth in 2013 with a rate of +46%. Insulin and insulin analogs are the recombinant protein products with strongest sales in 2013.
Interestingly, among the 37 companies selling recombinant biologics, only five achieved sales of more than US$ 10 bln in 2013. The cumulated biologics sales of these five companies were US$ 81.4 bln and make out 58% of all biologics sales in 2013.
The report „2013 Sales of Recombinant Therapeutic Antibodies & Proteins“ can be acquired at La Merie Publishing’s News Center and Online Store www.PipelineReview.com : http://pipelinereview.com/index.php/2013050950921/Press-Room/Blockbuster-Biologics-2012-sales-are-double-that-of-2006-driven-by-strong-growth-of-recombinant-antibodies.html
The report provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2013. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, published currency into US$. Sales figures represent the sum of revenues in all territories where the products are marketed.
Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2013 sales higher than US$ 1 bln. Another ranking list was prepared for companies according to biologics sales in 2013 and the percentage of antibody sales vs protein sales.
About La Merie Publishing
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.
PipelineReview.com is the Biologics News Center and Online Store of La Merie Publishing focused on Research and Development in the Biopharmaceutical Industry. FREE R&D Newletters conveniently bring via e-mail a daily or weekly selection of the most interesting news from biopharmaceutical R&D. For more information visit www.pipelinereview.com.
SOURCE: La Merie Publishing